Press releases

Angelini Pharma announced today that the EC has granted marketing authorization for ONTOZRY®.

Four thousand European citizens were interviewed by SWG on behalf of Angelini Pharma on the occasion of the Purple Day, the international day of awareness about epilepsy. According to the majority of respondents, people with epilepsy are perfectly normal people, but 40% would not talk about the disease at work.

Elma Research conducted three interviews with the presidents of three epilepsy-fighting organizations.

Through the acquisition, Angelini Pharma will be a major player in the market for treatment of central nervous system (CNS) and mental health disorders.

This acquisition will propel Angelini Pharma into a leading European player, well positioned to address the needs of patients with different CNS and mental disorders.

In his role, Ghirlanda reports directly to CEO Pierluigi Antonelli and joins the Executive Leadership Team, the Company's Steering Committee.

Social networks feature the events of the “Monelli family” to learn new health and hygiene habits in a fun, light-hearted manner. And on TikTok, rules become choreographies.

Promoting the development of corporate decision-making process powered by the use of data.

Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 (gaboxadol) for the potential treatment of Angelman Syndrome in Europe.

In her role she will report to CEO Pierluigi Antonelli and will be part of the Executive Leadership Team, the Company's Steering Committee.